Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
154.2 EUR | -1.46% |
|
+0.44% | +10.08% |
Jul. 12 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
Jul. 12 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The opinion of analysts covering the stock has improved over the past four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.55 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.08% | 301B | - | ||
+63.05% | 854B | C+ | ||
+39.42% | 636B | B | ||
-4.78% | 361B | C+ | ||
+17.52% | 324B | B- | ||
+14.19% | 247B | B+ | ||
+5.81% | 230B | A+ | ||
+16.77% | 228B | B- | ||
+14.63% | 177B | C+ | ||
+1.08% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
- Ratings AbbVie Inc.